Table 1.
Examples of plant-derived pharmaceuticals in clinical trials (data from U.S. National Institutes of Health Clinical Trial [18].
| Product | Host | Application | Clinical Trial | Status | Sponsor |
|---|---|---|---|---|---|
| Taliglucerase alfa; Recombinant glucocerebrosidase (prGCD) |
Carrot cell culture | Gaucher disease | NCT00376168 | Phase 3 completed (2012); FDA approved (2012) |
Protalix, Karmiel, Israel |
| ZMApp | Tobacco | Ebola Virus | NCT02363322 | Phase 1 and 2 (2015) | National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA |
| PRX-102 | Tobacco cell culture | Fabry Disease | NCT01769001 | Phase 1 and 2 (2014) | Protalix, Karmiel, Israel |
| VaccinePfs25 VLP | Tobacco | Malaria | NCT02013687 | Phase 1 (2015) | Center for Molecular Biotechnology, Plymouth, MI, USA |
| Vaccine Recombinant protective antigen | Tobacco | Anthrax | NCT02239172 | Phase 1 (2014) | Center for Molecular Biotechnology, Plymouth, MI, USA |
| HAI-05 | Tobacco | H5N1 Vaccine | NCT01250795 | Phase 1 (2011) | Center for Molecular Biotechnology, Plymouth, MI, USA |
| Recombinant human intrinsic factor | Arabidopsis thaliana | Vitamin B12 deficiency | NCT00279552 | Phase 2 Completed (2006) | University in Aarhus, Aarhus, Denmark |
| H5-VLP + GLA-AF Vaccine | Tobacco | Influenza A Subtype H5N1 Infection | NCT01657929 | Phase 1 Completed (2014) | Infectious Disease Research Institute, Seattle, WA, USA |
| P2G12 Antibody | Tobacco | HIV | NCT01403792 | Phase 1 Completed (2011) | University of Surrey, Guildford, UK |